We explored the efficacy and safety of the multitargeted antiangiogenic agent anlotinib and PD‐1/ PD‐L1 inhibitors combination therapy as second‐line or subsequent therapy for advanced SCLC. The gene discussed is PDCD1; the disease is small cell lung carcinoma.